JAK
Los inhibidores de la Janus quinasa (JAK) son compuestos que se dirigen a la vía de señalización JAK-STAT, la cual está involucrada en el crecimiento celular, la respuesta inmunitaria y la angiogénesis. Al inhibir JAK, estos compuestos pueden reducir la señalización que conduce a la formación de nuevos vasos sanguíneos en los tumores, inhibiendo así el crecimiento tumoral. Los inhibidores de JAK son importantes en el tratamiento del cáncer y las enfermedades inflamatorias. En CymitQuimica, ofrecemos una amplia gama de inhibidores de JAK de alta calidad para apoyar su investigación en oncología, inmunología y angiogénesis.
Productos de "JAK"
Ordenar por
JAK2-IN-6
CAS:JAK2-IN-6: A potent JAK2-specific inhibitor (IC50=22.86μg/mL), blocks JAK2 signaling, has anticancer properties, and is inactive against JAK1/3.Fórmula:C14H10ClN3OS2Pureza:99.38%Forma y color:SolidPeso molecular:335.83JAK3 covalent inhibitor-1
CAS:JAK3 Covalent Inhibitor-1 is a compound characterized by its potent and selective inhibition of Janus kinase 3 (JAK3), possessing an IC50 of 11 nM andFórmula:C22H17FN6O2SPureza:98%Forma y color:SolidPeso molecular:448.47Brepocitinib P-Tosylate
CAS:Brepocitinib P-Tosylate (PF-06700841 P-Tosylate) is a potent dual inhibitor of Janus kinase 1 (JAK1) and TYK2 (IC50s of 17 nM and 23 nM, respectively).Fórmula:C25H29F2N7O4SPureza:99.82% - 99.97%Forma y color:SolidPeso molecular:561.6Dual Cathepsin L/JAK-IN-1
CAS:DualCathepsinL/JAK-IN-1 (Compound A8) serves as a dual inhibitor of Cathepsin L (CTSL) and JAK, exhibiting IC50 values of 0.68 μM for CTSL and 337.1 nM, 5.251 nM, 27.29 nM, and 172.6 nM for JAK1/2/3 and TYK2, respectively. This compound effectively prevents the activation of MAPK, NF-κB, and JAK/STAT signaling pathways, leading to significant anti-inflammatory therapeutic effects. DualCathepsinL/JAK-IN-1 is applicable in research on acute lung injury (ALI).Fórmula:C19H18ClN5Forma y color:SolidPeso molecular:351.833Jaspamycin
CAS:Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα.Fórmula:C12H12N4O5Forma y color:SolidPeso molecular:292.25AT9283
CAS:AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).Fórmula:C19H23N7O2Pureza:99.83% - 99.98%Forma y color:SolidPeso molecular:381.43Ref: TM-T3068
1mg47,00€2mg60,00€5mg95,00€10mg170,00€25mg299,00€50mg499,00€100mg723,00€1mL*10mM (DMSO)97,00€Pacritinib
CAS:Pacritinib (SB1518) (SB1518) is an effective and specific inhibitor of JAK2 and FLT3 (IC50: 23/22 nM, in cell-free assays).Fórmula:C28H32N4O3Pureza:99.25% - 99.49%Forma y color:SolidPeso molecular:472.58Upadacitinib
CAS:Upadacitinib (ABT-494), a selective JAK1 inhibitor, is researched for autoimmune diseases; IC50: 43 nM.Fórmula:C17H19F3N6OPureza:98.96% - 99.93%Forma y color:SolidPeso molecular:380.37Ref: TM-T7503
1mg47,00€2mg62,00€5mg89,00€10mg130,00€25mg220,00€50mg306,00€100mg434,00€200mg662,00€500mg1.169,00€1mL*10mM (DMSO)48,00€Gandotinib
CAS:LY2784544(Gandotinib (LY2784544)) is a potent JAK2 inhibitor (IC50: 3 nM), effective in JAK2V617F(Ki: 0.245 nM).Fórmula:C23H25ClFN7OPureza:99.33% - 99.86%Forma y color:SolidPeso molecular:469.94Ref: TM-T2638
5mg51,00€10mg88,00€25mg160,00€50mg296,00€100mg469,00€500mg1.035,00€1mL*10mM (DMSO)57,00€JAK2-IN-7
CAS:JAK2-IN-7 selectively inhibits JAK2 (IC50: 3 nM), shows 14-fold selectivity over JAK1/3, FLT3, induces G0/G1 arrest, apoptosis, and has antitumor effects.Fórmula:C26H33N7OPureza:98.71%Forma y color:SolidPeso molecular:459.59Ref: TM-T35900
1mg145,00€5mg354,00€10mg630,00€25mg1.301,00€50mg1.738,00€100mg2.357,00€1mL*10mM (DMSO)358,00€AZ-3
CAS:AZ-3 is a potent and selective JAK1 inhibitor (IC50: 34 nM).Fórmula:C20H28FN7Pureza:98%Forma y color:SolidPeso molecular:385.48JAK-IN-28
CAS:JAK-IN-28 (Compound 111) is a Janus kinase (JAK) inhibitor potentially applicable in the research of cancer and inflammatory diseases [1].Fórmula:C20H18ClN7OPureza:98%Forma y color:SolidPeso molecular:407.86JBJ-04-125-02
CAS:JBJ-04-125-02: Oral EGFR inhibitor, targets EGFRL858R/T790M with 0.26 nM IC50, halts cancer growth, anti-tumor.Fórmula:C29H26FN5O3SPureza:98%Forma y color:SolidPeso molecular:543.61JAK3-IN-7
CAS:JAK3-IN-7 is a potent and selective JAK3 inhibitor (IC50<0.01 μM) for the treatment of rejection in organ transplantation, graft-versus-host reaction afterFórmula:C17H20N6OPureza:98.81%Forma y color:SolidPeso molecular:324.38Tyrphostin AG 490
CAS:Fórmula:C17H14N2O3Pureza:>98.0%(T)(HPLC)Forma y color:White to Light yellow powder to crystalPeso molecular:294.31DTP3
CAS:DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.Fórmula:C26H35N7O5Forma y color:SolidPeso molecular:525.6Pumecitinib
CAS:Pumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib exhibits anti-inflammatory activity.Fórmula:C17H20N8O2SPureza:99.89%Forma y color:SoildPeso molecular:400.46RGB-286638 free base
CAS:RGB-286638 free base inhibits CDKs (1-5 nM), weaker on CDK7/6.Fórmula:C29H35N7O4Pureza:97.29% - 99.91%Forma y color:SolidPeso molecular:545.63Fosifidancitinib
CAS:Fosifidancitinib is a potent inhibitor of JAK 1 and JAK 3.Fórmula:C21H21FN5O7PPureza:99.55%Forma y color:SolidPeso molecular:505.39Ref: TM-T38624
1mg87,00€2mg124,00€5mg187,00€10mg284,00€25mg452,00€50mg645,00€100mg867,00€200mg1.159,00€STAT3-IN-18
CAS:STAT3-IN-18 (compound SPP), a platinum (IV) complex featuring an axial ligand from sandalwood, suppresses the JAK2-STAT3 pathway in breast cancer (BC) cells andFórmula:C18H24Cl2N2O6PtPureza:98%Forma y color:SolidPeso molecular:630.38
